GlaxoSmithKline and Innoviva’s triple-combination therapy of fluticasone furoate, umeclidinium and vilanterol significantly reduced the amount of exacerbations experienced by patients with chronic ...
London, UK, Thursday 23 March 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing ...
GlaxoSmithKline plc and Innoviva, Inc. announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple ...
GlaxoSmithKline has filed with the European Medicines Agency its Innoviva-partnered, once-daily, closed triple combination therapy as a treatment for patients with chronic obstructive pulmonary ...
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) announced the approval of the company's Symbicort Turbuhaler in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve ...
GlaxoSmithKline has said its combination therapy for chronic obstructive pulmonary disease (COPD) has met its goal in a late-stage study by producing better results than an AstraZeneca rival. GSK said ...
LONDON, Oct 18 (Reuters) - AstraZeneca Plc lost a key European patent on its two-in-one asthma drug Symbicort on Thursday but the drugmaker said it did not expect the move to have an immediate impact ...
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback